2.175

1.40% 0.025

Ventyx Biosciences Inc (VTYX)

Overview News Price History Option Chain Financials Why VTYX Down? Discussions Forecast

Ventyx Biosciences Inc stock is traded at $2.175, with a volume of 326.31K. It is up +1.40% in the last 24 hours and up +3.81% over the past month. Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Previous Close:

$2.15

Open:

$2.15

24h Volume:

326.31K

Relative Volume:

0.29

Market Cap:

$153.71M

Revenue:

Net Income/Loss:

$-192.96M

P/E Ratio:

-0.7768

EPS:

-2.8

Net Cash Flow:

$-167.04M

1W Performance:

-8.79%

1M Performance:

+3.81%

6M Performance:

-55.05%

1Y Performance:

-86.01%

1-Day Range:

$2.14

$2.20

1-Week Range:

$2.10

$2.4302

52-Week Range:

$1.79

$15.80

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name

Ventyx Biosciences Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(858) 945-2393

Address

12790 EL CAMINO REAL, SUITE 200, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

VTYX's Discussions on Twitter

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-14-23	Resumed	Credit Suisse	Outperform
Mar-21-23	Initiated	Wells Fargo	Overweight
Dec-19-22	Initiated	Goldman	Buy
Nov-17-22	Initiated	Morgan Stanley	Overweight
Sep-07-22	Initiated	Stifel	Buy
Sep-01-22	Initiated	H.C. Wainwright	Buy
May-09-22	Initiated	Credit Suisse	Outperform
Mar-31-22	Initiated	Canaccord Genuity	Buy
Feb-01-22	Initiated	Oppenheimer	Outperform
Nov-15-21	Initiated	Jefferies	Buy
Nov-15-21	Initiated	Piper Sandler	Overweight

View All

Ventyx Biosciences Inc Stock (VTYX) Latest News

03:30 AM

Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com

03:30 AM

Nov 04, 2024

Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha

Nov 04, 2024

Oct 28, 2024

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider

Oct 28, 2024

Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat

Oct 28, 2024

Oct 17, 2024

HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat

Oct 17, 2024

Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com

Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com

Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK

Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire

Oct 16, 2024

Oct 15, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat

Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com

Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada

Oct 15, 2024

VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 15, 2024